Hematologic malignancies are a heterogeneous group of diseases with unique illness trajectories, treatment paradigms, and potential for curability, which affect patients’ palliative and end-of-life ...

Another disease-related barrier relates to the cytopenias experienced by many patients with HMs because of their disease or its treatment. Treatment of anemia and thrombocytopenia consists mainly of ...

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases. Improving end-of-life care for pediatric ...

A rare association exists between pulmonary hypertension (PH) and hematologic malignancies, particularly AML evolving from MPN. The case study involves a 32-year-old woman with JAK2 mutation-positive ...

Janssen Oncology’s Research & Development group focuses on specific tumor types with the greatest patient need, bringing together deep scientific expertise, understanding of disease biology, novel ...